Capital Markets

Capital Markets

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.

Key Contacts

Meet Our Team

Areas of Focus

Expand All Collapse All

Initial Public Offerings: A Practical Guide to Going Public

Initial Public Offerings: “A Practical Guide to Going Public” is the ultimate roadmap to the IPO process. Hailed by executives, entrepreneurs, general counsel, investment bankers and venture capitalists alike as the definitive IPO guide, this comprehensive resource charts every twist and turn on the IPO journey and provides battle-tested, real-world advice on how to navigate the roadblocks.

2020 IPO Report—A Detailed IPO Market Review and Outlook

Publications

Experience

  • Initial Public Offerings – Issuers

    Representing issuers, including Acacia Communications, Aileron Therapeutics, Akouos, Apellis Pharmaceuticals, Arsanis, Arvinas, Blue Apron, Casa Systems, Constellation Pharmaceuticals, EverQuote, Fulcrum Therapeutics, Generation Bio, IMARA, Inozyme Pharma, Kala Pharmaceuticals, Pandion Therapeutics, Schrödinger, Stealth BioTherapeutics, Syros Pharmaceuticals, Translate Bio and Trevi Therapeutics, in initial public offerings over the last three years.

  • Initial Public Offerings – Underwriters

    Representing underwriters in initial public offerings, including those of CarGurus, Dynatrace, Entasis Therapeutics, Forma Therapeutics, Milestone Pharmaceuticals, Rhythm Pharmaceuticals, TCR Therapeutics and Xeris Pharmaceuticals, over the last three years.
  • Follow-On Public Offerings and PIPE Placements

    Representing companies, including Agios Pharmaceuticals, Apellis Pharmaceuticals, AVEO Pharmaceuticals, Casella Waste Systems, Catabasis Pharmaceuticals, Conformis, Curis, Danaher, Editas Medicine, Epizyme, Farmer Mac, Franklin Street Properties, Iterum Therapeutics, Kala Pharmaceuticals, Nightstar Therapeutics, Spark Therapeutics, State Street and WEX, in follow-on public offerings and PIPE placements of common and preferred stock over the last three years.
  • Convertible Notes and Other Equity-Linked Securities

    Representing issuers, including Akamai Technologies, Apellis Pharmaceuticals, Danaher, Emergent BioSolutions, Fortive, Karyopharm Therapeutics and PTC Therapeutics, in Rule 144A placements and public offerings of convertible notes and other equity-linked securities.
  • Investment Grade and High-Yield Notes

    Representing issuers, including Analog Devices, Danaher, Discovery, Entegris, Houghton Mifflin Harcourt, Huntington Ingalls Industries, Intercept Pharmaceuticals, Medtronic, PerkinElmer, State Street, S&P Global, Thermo Fisher Scientific and WEX, in Rule 144A placements and public offerings of investment grade and high-yield notes.

Recognition

  • Award Text

    Recognized Among the Nation's Best for Capital Markets

    Chambers USA

    2020

  • Award Text

    Named a First-Tier National Firm for Securities/Capital Markets Law

    U.S. News - Best Lawyers®

    2020-2021

  • Award Text

    Recognized as a Leading Firm for Capital Markets 

    The Legal 500 United States

    2020

  • Chambers USA: America’s Leading Lawyers for Business – Ranked WilmerHale in Massachusetts for Capital Markets and in Massachusetts and Washington DC for Corporate/M&A.
  • Chambers Global – Recognized 34 WilmerHale lawyers and 27 practice areas in their 2020 edition.
  • Best Lawyers in America – Recognized 124 WilmerHale partners for 2020, naming 11 as “Lawyers of the Year.”
  • U.S. News - Best Lawyers® – Recognized in the 2010–2021 “Best Law Firms” rankings. In the 2021 rankings, our corporate, mergers and acquisitions, and venture capital law practices were ranked in the first tier nationally and in Boston, and our corporate law practice was also ranked in the first tier in New York and Washington DC and in the second tier in Colorado. Our securities/capital markets law practice was ranked in the first tier nationally and in Washington DC, and second tier in Boston. Our technology law practice was also ranked in the first tier in Boston and in the second tier nationally.
  • The Legal 500 United States – Regularly recognizes the firm in the areas of Finance: Capital Markets: Debt—Advice to Issuers and Finance: Capital Markets: Equity Offerings—Advice to Issuers, most recently in 2020.
  • Corporate Board Member – In 2014, 2016 and 2018, the most recent edition, WilmerHale was named to Top National Corporate Law Firms list, a comprehensive ranking of the top 25 firms in the nation. Results are based on law firm surveys and feedback from thousands of directors and general counsel.
  • LMG Life Sciences – Named WilmerHale the US Life Cycle Firm of the Year in 2017–2019 and among the shortlist from 2012–2020. LMG has also ranked the firm in its 2012–2020 editions in corporate, licensing and collaboration, M&A, venture capital and several other practice areas, and named many WilmerHale lawyers “life sciences stars.”
  • Law360 – Named WilmerHale a Technology Practice Group of the Year for 2016–2018, an award recognizing the firm’s key role in the significant matters that made headlines and changed the legal landscape within the past year. 
  • Super Lawyers – Our corporate lawyers are consistently recognized as “Super Lawyers” and “Rising Stars” in multiple jurisdictions.

Insights & News